Literature DB >> 1685662

The drug treatment of atrial fibrillation.

K S Channer1.   

Abstract

1. Atrial fibrillation is an inefficient cardiac rhythm associated with impaired exercise tolerance, exertional dyspnoea, palpitation and a substantial risk of thromboembolism. 2. The first decision in management is to consider cardioversion which can be achieved in suitable cases electrically, or pharmacologically with a class Ic antiarrhythmic drug like flecainide or propafenone. 3. Prophylaxis in paroxysmal atrial fibrillation is best achieved with a class Ic drug or a class III drug such as sotalol or amiodarone. 4. Control of ventricular rate in chronic atrial fibrillation can be achieved by pharmacological manipulation of the atrioventricular node by digoxin alone, or in combination with the calcium channel blockers verapamil or diltiazem, or beta-adrenoceptor blockers with intrinsic sympathomimetic activity like pindolol or xamoterol. 5. In view of the considerable risk of thromboembolism in patients with chronic atrial fibrillation anticoagulation or at least treatment with aspirin should be considered.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1685662      PMCID: PMC1368517          DOI: 10.1111/j.1365-2125.1991.tb03898.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  57 in total

1.  EFFECTS OF BETA-ADRENERGIC BLOCKADE WITH PROPRANOLOL IN PATIENTS WITH ATRIAL ARRHYTHMIAS.

Authors:  D C HARRISON; J R GRIFFIN; T J FIENE
Journal:  N Engl J Med       Date:  1965-08-19       Impact factor: 91.245

2.  Haemodynamic effect of intravenous verapamil in controlled atrial fibrillation.

Authors:  G Sloman; J Spokes; J Ramshaw; J Vohra
Journal:  Aust N Z J Med       Date:  1975-10

3.  The contribution of atrial systole to mitral diastolic blood flow increases during exercise in humans.

Authors:  K S Channer; J V Jones
Journal:  J Physiol       Date:  1989-04       Impact factor: 5.182

4.  Twenty four hour ambulatory electrocardiography in patients with chronic atrial fibrillation.

Authors:  D Pitcher; M Papouchado; M A James; J R Rees
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-01

5.  Immediate effects of intravenous verapamil on atrial fibrillation.

Authors:  L Schamroth
Journal:  Cardiovasc Res       Date:  1971-10       Impact factor: 10.787

6.  Restoration of sinus rhythm with flecainide in patients with atrial fibrillation.

Authors:  J J Goy; U Kaufmann; L Kappenberger; U Sigwart
Journal:  Am J Cardiol       Date:  1988-08-25       Impact factor: 2.778

7.  Effect of beta-adrenergic blockade on exercise performance in patients with chronic atrial fibrillation.

Authors:  J E Atwood; M Sullivan; S Forbes; J Myers; W Pewen; H G Olson; V F Froelicher
Journal:  J Am Coll Cardiol       Date:  1987-08       Impact factor: 24.094

8.  Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem.

Authors:  R V Lewis; N Irvine; D G McDevitt
Journal:  Eur Heart J       Date:  1988-07       Impact factor: 29.983

9.  Low- and medium-dose diltiazem in chronic atrial fibrillation: comparison with digoxin and correlation with drug plasma levels.

Authors:  I Maragno; G Santostasi; R M Gaion; M Trento; A M Grion; G Miraglia; S Dalla Volta
Journal:  Am Heart J       Date:  1988-08       Impact factor: 4.749

10.  Placebo controlled trial of xamoterol versus digoxin in chronic atrial fibrillation.

Authors:  E L Ang; W L Chan; J G Cleland; D Moore; S J Krikler; N D Alexander; C M Oakley
Journal:  Br Heart J       Date:  1990-10
View more
  5 in total

1.  Rate control in permanent atrial fibrillation.

Authors:  Theodora Nikolaidou; Kevin S Channer
Journal:  BMJ       Date:  2007-11-24

Review 2.  Current management of symptomatic atrial fibrillation.

Authors:  K S Channer
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  ABC of atrial fibrillation. Drugs for atrial fibrillation.

Authors:  G Y Lip; R D Watson; S P Singh
Journal:  BMJ       Date:  1995-12-16

4.  An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation.

Authors:  R P Steeds; A S Birchall; M Smith; K S Channer
Journal:  Heart       Date:  1999-08       Impact factor: 5.994

Review 5.  Diltiazem. A review of its pharmacology and therapeutic use in older patients.

Authors:  A Markham; R N Brogden
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.